Upstream Bio (NASDAQ:UPB) Shares Down 7.3% – What’s Next?

Upstream Bio, Inc. (NASDAQ:UPB)’s share price was down 7.3% on Tuesday . The company traded as low as $9.30 and last traded at $9.15. Approximately 7,240 shares were traded during trading, a decline of 98% from the average daily volume of 325,232 shares. The stock had previously closed at $9.87.

Upstream Bio Stock Down 5.4 %

The firm’s fifty day moving average is $9.32.

Hedge Funds Weigh In On Upstream Bio

A number of large investors have recently bought and sold shares of UPB. Moody Aldrich Partners LLC acquired a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $1,229,000. Rhumbline Advisers purchased a new stake in shares of Upstream Bio during the 4th quarter worth $275,000. US Bancorp DE acquired a new position in shares of Upstream Bio during the 4th quarter worth $27,000. Marshall Wace LLP acquired a new stake in shares of Upstream Bio during the 4th quarter valued at approximately $4,780,000. Finally, Summit Investment Advisors Inc. purchased a new stake in shares of Upstream Bio in the 4th quarter worth about $30,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.